Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.39 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754640 | 0.89 | POLB (0.41) | DPP8CHRM1KMT2AKDM4EALDH1A1 | |
| SCHEMBL25754638 | 0.88 | DPP8 (0.38) | DPP8CHRM1L3MBTL3L3MBTL1 | |
| SCHEMBL17152285 | 0.79 | DPP8 (0.53) | DPP8CYP3A4CYP2C19CHRM1L3MBTL3 | |
| SCHEMBL13030971 | 0.77 | DPP7 (0.50) | DPP8CYP3A4CYP2C19CHRM1L3MBTL3 | |
| SCHEMBL23514532 | 0.76 | DPP8 (0.49) | DPP8CYP3A4CYP2C19CHRM1L3MBTL3 | |
| SCHEMBL23514531 | 0.76 | DPP8 (0.49) | DPP8CYP3A4CYP2C19CHRM1L3MBTL3 | |
| SCHEMBL24963359 | 0.76 | DPP8 (0.55) | DPP8CHRM1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL15045187 | 0.75 | CYP3A4 (0.50) | DPP8CYP3A4CYP2C19CHRM1L3MBTL3 | |
| SCHEMBL25754642 | 0.73 | HRH3 (0.35) | CYP2C19L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL3592099 | 0.73 | DPP8 (0.47) | DPP8CYP3A4CYP2C19CHRM1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | DPP8 831/4885CYP3A4 3673/4885CYP2C19 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.